HRF 2105
Alternative Names: HRF-2105Latest Information Update: 18 Jan 2024
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Osteoarthritis
Most Recent Events
- 31 Oct 2023 Jiangsu HengRui Medicine plans a phase II trial for Osteoarthritis in October 2023 (NCT06047483)
- 29 Sep 2023 Preclinical trials in Osteoarthritis in China (unspecified route)